Skip to search formSkip to main contentSkip to account menu

UK 453,061

Known as: UK453061, UK 453061, UK-453061 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

NitrilesPyrazoles

Narrower (1)

lersivirine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients: Week 48 Primary Analysis Results From an Ongoing, Multicenter, Randomized…
Objective:A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… 
2012
2012
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized…
OBJECTIVE A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… 
Review
2010
Review
2010
Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors
HIV type-1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy… 
Highly Cited
2010
Highly Cited
2010
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1
ABSTRACT The nonnucleoside reverse transcriptase inhibitors (NNRTIs) are key components of highly active antiretroviral therapy… 
2010
2010
Excretion and Metabolism of Lersivirine (5-{[3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor…
Lersivirine [UK-453,061, 5-((3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile] is a next… 
2009
2009
Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations
The requirements for safe testing of pharmaceuticals in humans places substantial emphasis on the translation of safety testing… 
Review
2009
Review
2009
Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1
Since the introduction of the HAART, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have played an essential role in… 
Review
2008
Review
2008
Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
Efavirenz non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy or boosted protease inhibitor (PI)-based therapy… 
2008
2008
Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral…
1. UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus… 
2008
2008
The rise of second-generation non-nucleoside reverse transcriptase inhibitors: Etravirine, rilpivirine, UK-453061 and RDEA-806
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)